PTO/SB/25 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMED TO OPMATE A PROMISIONAL POWER TO A PROMISIONAL PROMISIONAL

TERMINAL DISCLAIMI	ER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)
REJECTION O	VER A PENDING "REFERENCE" APPLICATION	559662000101
In re Application of:	Bruce Joseph ROSER	
Application No.:	09/888,734	
Filed:	June 25, 2001	
For:	DRIED BLOOD FACTOR COMPOSITION COMPRISING TREHALOSE	
The owner, Quadrant Drug Delivery Limited , of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,649,386, Application Number 08/875,796 filed 30 October 1998, or of any patent granted on pending reference Application Numbers 10/658,219 filed 8 September 2003; 10/679,723 filed 6 October 2003; and 10/681,948 filed 8 October 2003, as such term is defined in 35 U.S.C. 154 and 173, and as the term of said patent or of said reference applications may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference applications. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any said patent or patent granted on the reference applications are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of said patent or any patent granted on said reference applications, "in the event that: said patent or any patent granted or fany patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: said patent or any patent granted on the pending reference application, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer file		
	. §§ 155-156 or adjustment of patent term pursuant to 35 U.S.C. § 1 ic law or act which provides for extension of term of a patent. elow if appropriate	54(b) or pursuant to any other
1. For submission	s on behalf of a business/organization (e.g., corporation, partnership signed is empowered to act on behalf of the business/organization.	, university, government agency,
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.  2. X The undersigned is an attorney or agent of record. Reg. No.		
Z. X The undersigne	d is an attorney or agent or record. Heg. No. 29,959	
	/Kate H. Murashige/ Signature	March 23, 2007
	Signature	Date
Kate H. Murashige		
	Typed or printed name	(050) 700 5140
		(858) 720-5112 Telephone Number
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
	3.73(b) is required if terminal disclaimer is signed by the assignee (oused for making this statement. See MPEP § 324.	wner).
1		